Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12322748 | 0.91 | DHFR (0.37) | RAPGEF4DHFRCYP3A4HTR2ASLC6A4 | |
| SCHEMBL9231490 | 0.84 | POLB (0.37) | KCNH2 | |
| SCHEMBL18807949 | 0.83 | RAPGEF4 (0.37) | RAPGEF4HTR2ASLC6A4KCNH2 | |
| SCHEMBL27400140 | 0.82 | ALDH1A1 (0.34) | RAPGEF4HTR2ASLC6A4KCNH2 | |
| SCHEMBL19199592 | 0.79 | CD44 (0.42) | RAPGEF4CYP3A4 | |
| SCHEMBL15935764 | 0.79 | RAPGEF4 (0.34) | RAPGEF4 | |
| SCHEMBL19198539 | 0.79 | HDAC1 (0.31) | RAPGEF4 | |
| SCHEMBL24456167 | 0.77 | TSHR (0.36) | CYP3A4 | |
| SCHEMBL29279175 | 0.77 | KDM1A (0.41) | — | |
| SCHEMBL13973185 | 0.76 | CD44 (0.36) | RAPGEF4DHFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | RAPGEF4 1632/4885DHFR 1059/4885CYP3A4 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.